Q4 Earnings Forecast for GPCR Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its Q4 2025 EPS forecast for Structure Therapeutics, lowering it from $2.58 to $2.51, while the company recently reported a loss of ($0.36) per share for Q2, missing consensus estimates.
• A number of brokerages have set varying price targets for Structure Therapeutics, with an average target of $75.71 and a consensus rating of "Buy" from eight research analysts.
• Currently, 91.78% of Structure Therapeutics' stock is owned by institutional investors and hedge funds, indicating strong institutional confidence in the company.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Investment analysts at Leerink Partnrs dropped their Q4 2025 earnings per share (EPS) estimates for Structure Therapeutics in a research note issued to investors on Thursday, August 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $2.51 for the quarter, down from their prior estimate of $2.58. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

Several other brokerages also recently commented on GPCR. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. HC Wainwright reduced their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research note on Thursday. Guggenheim decreased their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday. Citigroup initiated coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target for the company. Finally, JMP Securities reduced their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research report on Thursday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded up $0.11 during trading hours on Friday, hitting $16.31. 1,139,225 shares of the stock were exchanged, compared to its average volume of 881,394. The stock has a market capitalization of $935.22 million, a P/E ratio of -15.53 and a beta of -1.89. The business's 50-day moving average is $19.78 and its two-hundred day moving average is $21.81. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $45.37.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in Structure Therapeutics during the 4th quarter worth about $34,000. National Bank of Canada FI grew its position in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after buying an additional 2,766 shares during the period. Assetmark Inc. raised its stake in shares of Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after buying an additional 820 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after buying an additional 3,213 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.